SCHEMBL1785904

SCHEMBL1785904

CC(C(=O)O)c1c(F)cc2ncccc2c1F

nearest known ligand 0.47

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MET P08581 18/20 0.47
AKR1C3 P42330 2/20 0.46
AKR1C2 P52895 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1163429 0.85 MET (0.49) MET
SCHEMBL1163230 0.84 MET (0.46) MET
SCHEMBL29870612 0.82 MET (0.47) MET
SCHEMBL6520083 0.82 MET (0.47) MET
SCHEMBL12343890 0.82 MET (0.49) MET
SCHEMBL29869885 0.80 MET (0.47) MET
SCHEMBL28864786 0.80 MET (0.47) MET
SCHEMBL6519730 0.80 MET (0.47) MET
SCHEMBL29869638 0.80 MET (0.47) MET
SCHEMBL12337996 0.79 MET (0.47) MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102459283-B Aminopyrazole triazolothiadiazole inhibitors of C-MET protein kinase VERTEX PHARMA 2014-11-12 CN disclosed
EP-2673277-A1 [1, 2, 4]TRIAZOLO [4, 3 -B]PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE Novartis AG (CH) 2013-12-18 EP disclosed
US-20130324526-A1 [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE NOVARTIS AG (CH) 2013-12-05 US disclosed
EP-2435443-B1 AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTIEN KINASE VERTEX PHARMA (US) 2013-07-31 EP disclosed
EP-2435443-B1 AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTIEN KINASE VERTEX PHARMA (US) 2013-07-31 EP disclosed
US-20130018072-A1 AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTEIN KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-17 US disclosed
US-20130018072-A1 AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTEIN KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-17 US disclosed
US-20130018072-A1 AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTEIN KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-17 US disclosed
US-8269012-B2 Aminopyrazole triazolothiadiazole inhibitors of c-met protein kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-09-18 US disclosed
US-8269013-B2 Substituted pyrazole inhibitors of c-Met protein kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-09-18 US disclosed
WO-2010138665-A1 AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTIEN KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-02 WO disclosed
WO-2010138665-A1 AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTIEN KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-02 WO disclosed
WO-2010138673-A1 INHIBITORS OF C-MET PROTEIN KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-02 WO disclosed
WO-2010138673-A1 INHIBITORS OF C-MET PROTEIN KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-02 WO disclosed
WO-2010138663-A1 SUBSTITUTED PYRAZOLE INHIBITORS OF C-MET PROTEIN KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-02 WO disclosed
WO-2010138663-A1 SUBSTITUTED PYRAZOLE INHIBITORS OF C-MET PROTEIN KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-02 WO disclosed
US-20100305156-A1 INHIBITORS OF C-MET PROTEIN KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-02 US disclosed
US-20100305156-A1 INHIBITORS OF C-MET PROTEIN KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-02 US disclosed
US-20100305156-A1 INHIBITORS OF C-MET PROTEIN KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-02 US disclosed
US-20100305155-A1 SUBSTITUTED PYRAZOLE INHIBITORS OF C-MET PROTEIN KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305155-A1 SUBSTITUTED PYRAZOLE INHIBITORS OF C-MET PROTEIN KINASE MET, BRAF, DMPK MET 1/4885AKR1C3 2293/4885AKR1C2 2870/4885
US-20100305156-A1 INHIBITORS OF C-MET PROTEIN KINASE MET, BRAF, HGF MET 1/4885AKR1C3 2192/4885AKR1C2 2577/4885
US-20130324526-A1 [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE MET, ERBB2, RET MET 1/4885AKR1C3 2406/4885AKR1C2 3020/4885
US-20130018072-A1 AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTEIN KINASE MET, ABL1, DMPK MET 1/4885AKR1C3 2470/4885AKR1C2 2888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.